

REFERENCIAS BIBLIOGRÁFICAS

1. Akgun E, Caliskan C, Bozbiyik O, Yoldas T, Sezak M, Ozkok S, et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. *Br J Surg* 2018;105(11):1417-25.
2. Arian SE, Goodman L, Flyckt RL, Falcone T. Ovarian transposition: a surgical option for fertility preservation. *Fertil Steril* 2017;107(4):e15.
3. Aschele C, Pinto C, Cordio S, Rosati G, Tagliagambe A, Artale S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. *J Clin Oncol* 2009;27:18s (suppl; abstr CRA4008).
4. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CA, Putter CH, Meershoek-Klein Kranenberg E, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2021;22(1):29-42.
5. Baik SH, Nam Kyu Kim NK, Lee KY, Sohn SK, Cho ChH. Analysis of Anal Sphincter Preservation Rate According to Tumor Level and Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. *J Gastrointest Surg* 2008;12:176-82.
6. Barbaro B, Fiorucci C, Tebala C, Valentini V, Gambacorta MA, Vecchio FM, et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. *Radiology* 2009;250(3):730-9.
7. Battersby N, Dattani M, Rao S, Cunningham D, Tait D, Adams R, et al. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumor regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. *Trials* 2017;18(1):394 DOI: 10.1186/s13063-017-2085-2
8. Bernier L, Balyasnikova S, Tait D, Brown G. Watch-and-Wait as a therapeutic strategy in rectal cancer. *Curr Colorectal Cancer Rep* 2018;14(2):37-55.
9. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. *JAMA* 2011;305(22):2335-42.
10. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. *J Clin Oncol* 2005;23(34):8697-705.
11. Bonnel C, Parc YR, Pocard M, Dehni N, Caplin C, Parc R, Tiret E. Effects of preoperative radiotherapy for primary resectable rectal adenocarcinoma on male sexual and urinary function. *Dis Colon Rectum* 2002;45(7):934-9.
12. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. *J Clin Oncol* 2005;23(24):5620-7.
13. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med* 2006;355(11):1114-23.
14. Bouliis-Wassif S, Gerard A, Loygue J, Camelot D, Buyse M, Duez N. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. *Cancer* 1984;53(9):1811-8.
15. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. *Cancer* 2002;94(4):1121-30.
16. Breugom AJ, Swets M, Bosset JF, Colette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol* 2015;16(2):200-7.
17. Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CB, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. *Ann Oncol* 2015;26(4):696-701.
18. Bujko K, Bujko M. Point: short-course radiation therapy is preferable in the neoadjuvant treatment of rectal cancer. *Semin Radiat Oncol* 2011;21(3):220-7.
19. Bujko K, Kepka L, Michalski W, Nowacki MP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. *Radiother Oncol* 2006;80(1):4-12.
20. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg* 2006;93(10):1215-23.
21. Bujko K, Richter P, Smith FM, Polkowski W, Szczepkowski M, Rutkowski A, et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study. *Radiother Oncol* 2013;106(2):198-205.
22. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudelko M, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. *Radiother Oncol* 2004;72(1):15-24.
23. Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D. MRI directed multidisciplinary team preoperative treatment strategy: The way to eliminate positive circumferential margins? *Br J Cancer* 2006;94(3):351-7.
24. Butte JM, Gonen M, Ding P, Goodman KA, Allen PJ, Nash GM, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. *Cancer* 2012;118(21):5414-23.
25. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. *JAMA* 2000;284(8):1008-15.
26. Cassidy RJ, Liu Y, Patel K, Zhong J, Steuer CE, Kooby DA, et al. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base. *Cancer* 2017;123(5):783-93.
27. Castro CG, Santasusana JM, Herrero FR, Soler RS, García IS, Casado DI et al. SEOM clinical guidelines for the adjuvant treatment of colorectal cancer. *Clin Transl Oncol* 2010;12(11):724-728.

28. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. *Cochrane Database Syst Rev* 2009;(1):CD006041.
29. Cercek A, Roxburgh CSD, Strombom P, Joshua Smith J, Temple LK, Mash GM, et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. *JAMA Oncol* 2018;4(6):e180071.
30. Chan E, Wise PE, Chakravarthy AB. Controversies in radiation for upper rectal cancers. *JNCCN* 2012;10(12):1567-72.
31. Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. *Cancer* 2009;115(23):5432-40.
32. Chapman W., Roxburgh C., Makhdoom B., Roy A. et al. Rectal Cancer Downstaging is Significantly Improved with Different Regimens of Total Neoadjuvant Therapy. *Inter J Rad Oncol Biology Physics*. 2018;102(3):S65-S6.
33. Chau I, Brown G, Cunningham D, tait D, Wotherspoon A, Norman AR, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. *J Clin Oncol* 2006;24(4):668-74.
34. Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, et al. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. *J Am Coll Surg* 2005;200(6):876-82.
35. Chessin DB, Hartley J, Cohen AM, Mazumdar M, Cordeiro P, Disa J, et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. *Ann Surg Oncol* 2005;12(2):104-10.
36. Chmielik E, Bujko K, Nasierowska-Guttmejer A, Nowacki MP, Kepka L, Sopylo R, et al. Distal intramural spread of rectal cancer after preoperative radiotherapy: the results of a multicenter randomized clinical study. *Int J Radiat Oncol Biol Phys* 2006;65(1):182-8.
37. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. *Lancet Oncol* 2010;11(3):241-8.
38. Cionini L, Manfredi B, Sainato A, Panichi M, Friso M, Valentini V, et al. Randomized study of postoperative chemotherapy (CT) after preoperative chemoradiation (CTRT) in locally advanced rectal cancer (LARC). Preliminary results. *Eur J Cancer* 2001;37(suppl 6):S300 (abstr 1107).
39. Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. *Ann Oncol* 2019;30(8):1298-303.
40. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. *J Clin Oncol* 2007;25(28):4379-86.
41. Conroy T, Lamfichekh N, Etienne PL, Rip E, Francois E, Mesgouez-Nebout N, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. *J Clin Oncol* 2020;38S:ASCO #4007.
42. Cotte E, Passot G, Decullier E, Maurice C, Glehen O, François Y, et al. Pathologic Response, When Increased by Longer Interval, Is a Marker but Not the Cause of Good Prognosis in Rectal Cancer: 17-year Follow-up of the Lyon R90-01 Randomized Trial. *Int J Radiat Oncol Biol Phys* 2016;94(3):544-53.
43. Covens AL, van der Putten HW, Fyles AW, Leung PM, O'Brien PF, Murphy KJ, DePetrillo AD. Laparoscopic ovarian transposition. *Eur J Gynaecol Oncol* 1996;17(3):177-82.
44. Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J, Sawaf HB, et al. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. *Int J Radiat Oncol Biol Phys* 2001;49(1):107-16.
45. de Jong EA, ten Berge JC, Dwarkasing RS, Rijkers AP, van Eljck CH. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis. *Surgery* 2016;159(3):688-99.
46. Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. *J Clin Oncol* 2019;37(34):3223-33.
47. Dossa F, Acuna SA, Rickles AS, Berho M, Wexner SD, Quershy FA, et al. Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection. *JAMA Oncol* 2018;4(7):930-7.
48. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2017;2(7):501-13.
49. Dresen RC, Beets GL, Rutten HJ, Engelen SM, Lahaye MJ, Vliegen RF, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumor confined to the rectal wall? *Radiology* 2009;252(1):71-80.
50. Dubois JB, Bussieres E, Richaud P, Rouanet P, Becouarn Y, Mathoulin-Pelissier S, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. *Radiation Oncol* 2011;98(3):298-303.
51. Enker WE., Laffer UT. Block GE. Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. *Ann Surg* 1979;190(3):350-360.
52. Evans J, Patel U, Brown G. Rectal cancer: primary staging and assessment after chemoradiotherapy. *Semin Radiat Oncol* 2011;21(3):169-77.
53. Farber LA, Ames JW, Rush S, Gal D. Laparoscopic ovarian transposition to preserve ovarian function before pelvic radiation and chemotherapy in a young patient with rectal cancer. *Med Gen Med* 2005;7(1):66.
54. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. *J Clin Oncol* 2010;28(5):859-65.
55. Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. *Ann Oncol* 2015;26(8):1722-8.
56. Fietkau R, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. *Dis Colon Rectum* 2006;49(9):1284-92.
57. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. *J Natl Cancer Inst* 1988;80(1):21-9.
58. Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. *J*

- Clin Oncol 2019;37(34):3212-22.
59. Fokas E, Liersch T, Fietkau R, Hohemberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. *J Clin Oncol* 2014;32(15):1554-62.
 60. Foster JD, Ewings P, Falk S, Cooper EJ, Roach H, West NP, et al. Surgical timing after chemoradiotherapy for rectal cancer, analysis of technique (STARRCAT): results of a feasibility multi-centre randomized controlled trial. *Tech Coloproctol* 2016;20(10):683-93.
 61. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. *J Clin Oncol* 1999;17(8):2396-402.
 62. Fujita S, Yamamoto S, Akasu T, Moriya Y. Lateral pelvic lymph node dissection for advanced lower rectal cancer. *Br J Surg* 2003;90(12):1580-5.
 63. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA, et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. *Dis Colon Rectum* 2003;46(3):298-304.
 64. Garcia-Aguilar J, Patil S, Kim JK, Yuval JB, Thompson H, Verheij F, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. *J Clin Oncol ASCO* 2020;38(15S):pp4008.
 65. Garcia-Aguilar J, Smith DD, Avila K, Bergsland K, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal Timing of Surgery after Chemoradiation for Advanced Rectal Cancer: Preliminary Results of a Multi-center, Nonrandomized Phase II Prospective Trial. *Ann Surg* 2011;254(1):97-102.
 66. Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Response to Chemoradiation Consortium Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial *Lancet Oncol*. 2015;16(8):957-966.
 67. Garcia-Aguilar J, Renfro L, Chow OS, Shi Q, Carrero XW, Lynn P, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. *Lancet Oncol* 2015;16(15):1537-1546.
 68. Gavioli, M.; Luppi, G.; Losi, L.; Bertolini, F.; Santantonio, M.; Falchi, A.M.; D'Amico, R.; Conte, P.F.; Natalini, G. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. *Dis Colon Rectum* 2005;48(10):1851-57.
 69. Gérard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). *Ann Surg* 1988;208(5):606-14.
 70. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P-L, et al. Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodigé 2. *J Clin Oncol* 2010;28(10):1638-44.
 71. Gerard JP, Chapet O, Ramaoli A, Romestaing P. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. *Int J Radiat Oncol Biol Phys* 2002;54(1):142-9.
 72. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. *J Clin Oncol* 2006; 24:4620.
 73. Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. *Ann Oncol* 2014;25(7):1356-62.
 74. Gollins S, Moran B, Adams R, Cunningham C, Bach S, Myint AS, et al. Association of Coloproctology of Great Britain and Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Multidisciplinary Management. *Colorectal Disease* 2017;19(Suppl. 1):37-66.
 75. Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua JL 3rd, Gonen M, et al. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. *Eur Radiol* 2012;22(4):821-31.
 76. Grann A, Minsky BD, Cohen AM, Saltz L, Guillem JG, Paty PB, et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Preoperative combined modality treatment for rectal cancer. *Dis Colon Rectum* 1997;40(5):515-22.
 77. Guillem J, Ruby J, Leibold T, Akhurst T, Yeung H, Gollub M, et al. Neither FDG-PET nor TC can distinguish between a pathological complete response and incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. *Ann Surg* 2013;258(2):289-95.
 78. Guillem JG, Díaz-González JA, Minsky BD, Valentini V, Jeong S-Y, Rodríguez Bigas MA, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. *J Clin Oncol* 2008;26(3):368-73.
 79. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. *Ann Surg* 2005;241(5):829-38.
 80. Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. *J Clin Oncol* 2005;23(15):3475-9.
 81. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro Jr U, Silva e Sousa AH, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. *J Gastrointest Surg* 2005;9(1):90-9.
 82. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Jr J, Silva e Sousa AH, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg* 2004;240(4):711-8.
 83. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro Jr J, Silva e Sousa AH, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. *J Gastrointest Surg* 2005;9(1):90-9.
 84. Habr-Gama A, Perez RO. Non-operative management of rectal cancer after neoadjuvant chemoradiation. *Br J Surg* 2009;96(2):125-7.
 85. Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. *Colorectal Dis* 2006;8(s3):21-4.
 86. Hallam S, Messenger DE, Thomas MG. A Systematic Review of Local Excision After Neoadjuvant Therapy for Rectal Cancer: Are ypT0 Tumors the Limit? *Dis Colon Rectum* 2016;59(10):984-97.
 87. Hanly AM, Ryan EM, Rogers AC, Mc Namara DA, Madoff RD, Winter DC, MERRION Study Group. Multicenter Evaluation of Rectal cancer ReImaging pOst Neoadjuvant (MERRION) Therapy. *Ann Surg* 2014;259(4):723-7.
 88. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. *Int J Clin Oncol* 2020 Jan;25(1):1-42.
 89. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crelin A, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. *Radiother Oncol* 2009;92(2):210-4.

90. Hav M, Libbrecht L, Ferdinande L, Geboe K, Pattyn P, Cuvelier CA. Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications. *BioMed Research International* Volume 2015, Article ID 574540.
91. He F, Ju HQ, Ding Y, Jiang Z, Li Z, Huang B, et al. Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. *Br J Cancer* 2020;123(8):1244-52.
92. Heald RJ, Karanjia ND. Results of radical surgery for rectal cancer. *World J Surg* 1992;16(5):848-57.
93. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. *Arch Surg* 1998;133(8):894-9.
94. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. *J Am Coll Surg* 2002;194:131-135.
95. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. *Lancet Oncol* 2012;13(6):579-88.
96. Hojo K, Koyama Y, Moriya Y. Lymphatic spread and its prognostic value in patients with rectal cancer. *Am J Surg* 1982;144(3):350-4.
97. Hojo T, Sawada Y, Moriya Y. An analysis of survival and voiding, sexual function after wide ilio pelvic lymphadenectomy in patients with carcinoma of the rectum, compared with conventional lymphadenectomy. *Dis Colon Rectum* 1989;32(2):128-33.
98. Holliday EB, Hunt A, You YN, Chang GJ, Skibber JM, Rodriguez-Bigas MA, et al. Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. *J Gastrointest Oncol* 2017;8(6):990-7.
99. Hong YS, Kim SY, Lee JS, Nam B-H, Kim K-P, Kim JE, et al. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. *J Clin Oncol* 2019;37(33):3111-23.
100. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. *Lancet Oncol* 2014;15(11):1245-53.
101. Hughes R, Glynn-Jones R, Grainger J, Richman P, Makris A, Harrison M, et al. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? *Int J Colorectal Dis* 2006;21(1):11-7.
102. Hüttner FJ, Probst P, Kalkum E, Hackbusch M, Jensen K, Ulrich A, et al. Addition of Platinum Derivatives to Fluoropyrimidine-Based Neoadjuvant Chemoradiotherapy for Stage II/III Rectal Cancer: Systematic Review and Meta-Analysis. *J Natl Cancer Inst* 2019;111(9):887-902.
103. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. *Am J Clin Oncol* 2001;24(2):107-12.
104. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. *Int J Radiat Oncol Biol Phys* 1999;44(5):1027-38.
105. Johnston MJ, Robertson GM, Frizelle FA. Management of late complications of pelvic radiation in the rectum and anus: a review. *Dis Colon Rectum* 2003;46(2):247-59.
106. Jonas J, Bähr R. Neoadjuvant chemoradiation treatment impairs accuracy of MRI staging in rectal carcinoma. *Gut* 2006;55(8):1214-5.
107. Joye I, Deroose CM, Vandecaveye V, Haustermans K. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. *Radiother Oncol* 2014;113(2):158-65.
108. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med* 2001;345(9):638-46.
109. Karagkounis G, Stocchi L, Lavery IC, Liska D, Gorgun E, Veniero J, Plesce T, Amarnath S, Khorana AA, Kalady MF. Multidisciplinary conference and clinical management of rectal Cancer. *J Am Coll Surg* 2018;226(5):874-880.
110. Karagkounis G, Thai L, Mace AG, Wiland H, Pai RK, Steele SR, Church JM, Kalady MF. Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer. *Ann Surg* 2019;269(6):1117-23.
111. Kariv Y, Kariv R, Hammel JP, Lavery IC. Postoperative radiotherapy for stage IIIA rectal cancer: is it justified? *Dis Colon Rectum* 2008;51(10):1459-66.
112. Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, et al. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2020;3(12):e2030097.
113. Kennedy E, Simunovic M, Jhaveri K, Kirsch R, Brierley J, Drolet Sébastien, et al. Safety and feasibility of using magnetic resonance imaging criteria to identify patients with "good prognosis" rectal cancer eligible for primary surgery. The phase 2 nonrandomized QuickSilver clinical trial. *JAMA Oncol* 2019;5(7):961-966.
114. Kim DW, Kim DY, Kim TH, Jung KH, Chang HJ, Sohn DK, et al. Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer? *Cancer* 2006;106(8):1694-700.
115. Kim DW, Lim B, Kim DY, Kim TH, Jung KH, Kim DH, et al. Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge. *Eur J Surg Oncol* 2006;32(2) 162-7.
116. Kim HS, Kim NK. Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer. *Ann Gastroenterol Surg* 2020;4(4):379-85.
117. Kim JW, Kim YB, Kim NK, Min B-S, Shin SJ, Ahn JB, et al. The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. *Radiat Oncol* 2010;5:75.
118. Kim SH, Lee JM, Hong SH, Kim GY, Lee JW, Han JK, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. *Radiology* 2009;253 1)116-25.
119. Klos CL, Shellito PC, Rattner DW, Hodin RA, Cusack JC, Bordeianou L, et al. The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery. *Am J Surg* 2010;200(4):440-5.
120. Köckerling F, Reymond MA, Altendorf-Hofmann A, Dworak O, Hohenberger W. Influence of surgery on metachronous distant metastases and survival in rectal cancer. *J Clin Oncol* 1998;16(1):324-9.
121. Krdzalic J, Beets-Tan RGH, Engelen SME, van Griethuysen J, Lahaye MJ, Lambregts DMJ, Bakers FCH, Vliegen RFA, Beets GL, Maas M. MRI predicts increased eligibility for sphincter preservation after CRT in low rectal cancer. *Radiother Oncol* 2020;145:223-228.
122. Kristiansen C, Loft A, Berthelsen AK, Graff J, Lindebjerg J, Bisgaard C, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. *Dis Colon Rectum* 2008;51(1):21-5.
123. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. *N Engl J Med* 1991;324(11):709-15.
124. Kulaylat AS, Hollenbeak CS, Stewart DB Sr. Adjuvant Chemotherapy Improves Overall Survival of Rectal Cancer Patients

- Treated with Neoadjuvant Chemoradiotherapy Regardless of Pathologic Nodal Status. *Ann Surg Oncol* 2017;24(5):1281-8.
125. Lambregts DM, Maas M, Riedl RG, Bakkers FCH, Verwoerd JL, Kessels AGJ, et al. Value of ADC measurements for nodal staging after chemoradiation in locally advanced rectal cancer—a per lesion validation study. *Eur Radiol* 2011;21(2):265-73.
 126. Lambregts DM, Vandecaveye V, Barbaro B, Bakkers FCH, Lambrecht M, Maas M, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. *Ann Surg Oncol* 2011;18(8):2224-31.
 127. Lan YT, Jiang JK, Chang SC, Yang SH, Lin CC, Lin HH, Wang HS, Chen WS, Lin TC, Lin JK. Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams. *Int J Colorectal Dis* 2016;31(2):403-11.
 128. Latkauskas T, Pauzas H, Gineikiene I, Janciauskiene R, Juozaityte E, Saladzinskas Z, et al. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemo-radiotherapy, both with delayed surgery. *Colorectal Dis* 2012;14(3):294-8.
 129. Lefevre JH, Mineur L, Kotti S, Rullier R, Rouanet P, de Chaisemartin C, et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). *J Clin Oncol* 2016;34(31):3773-80.
 130. Leiro F, Roca E, Mospane C, Barugel M, Labiano S, Méndez G, et al. Respuesta clínica y patológica luego del tratamiento neoadyuvante en el cáncer de recto. *Rev Argent Ciruj* 2010;99(3-4):83-94.
 131. Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuite R, Guerrieri M. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total meso- rectal excision for T2 rectal cancer after neoadjuvant therapy. *Br J Surg*. 2012;99(9):1211-8.
 132. Loos M, Quentmeier P, Schuster T, Nitsche U, Gertier R, Keerl A, et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis. *Ann Surg Oncol* 2013;20(6):1816-28.
 133. Lundby L, Krogh K, Jensen VJ, Gandrup P, Qvist N, Overgaard J, et al. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. *Dis Colon Rectum* 2005;48(7):1343-9.
 134. Maas M, Lambregts DM, Nelemans PJ, Haijnen LA, Martens MH, Leijtens JWA, et al. Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment. *Ann Surg Oncol* 2015;22(12):3873-80.
 135. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo L-J, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. *Lancet Oncol* 2010;11(9):835-44.
 136. Madbouly, KM., Hussein AM. Changing Operative Strategy from Abdominoperineal Resection to Sphincter Preservation in T3 Low Rectal Cancer after Downstaging by Neoadjuvant Chemoradiation: A Preliminary Report Poster presentation (p354) at the ASCRS annual meeting 2014, Hollywood, FL World J Surg Published online 06 Jan 2015 DOI 10.1007/s00268-014-2930-3.
 137. Maffione AM, Marzola MC, Capirci C, Colletti PM, Rubello D.. Value of 18F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. *AJR Am J Roentgenol* 2015;204:1261-68.
 138. Marco M, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, et al. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. *Dis Colon Rectum* 2018; 61(10):1146-55.
 139. Maretto I, Pomerri F, Pucciarelli S, Mescoli C, Belluco C, Burzi S, et al. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. *Ann Surg Oncol* 2007;14(2):455-61.
 140. Marijnen CA, Kapiteijn E, van de Velde CJ, Martijn H, Steup WH, Wiggers T, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. *J Clin Oncol* 2002;20(3):817-25.
 141. Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. *J Clin Oncol* 2005;23(9):1847-58.
 142. Markovina DS., Youssef F., Roy A., Aggarwal S., Khwaja S, DeWees T, et al. Improved Metastasis- and Disease-Free Survival with Preoperative Sequential ShortCourse Radiotherapy and FOLFOX Chemotherapy for Rectal Cancer Compared toNeoadjuvant Long Course Chemoradiotherapy; Results of a Matched Pair Analysis. *Int J Radiat Oncol Biol Phys* 2017;99(2):417-26.
 143. Marks JH, Valsdottir EB, Rather AA, Nweze IC, Newman DA, Chernick MR. Fewer than 12 lymph nodes can be expected in a surgical specimen after high-dose chemoradiation therapy for rectal cancer. *Dis Colon Rectum* 2010;53(7):1023-9.
 144. Martin JR, Kodaman P, Oktay K, Taylor HS. Ovarian cryopreservation with transposition of a contralateral ovary: a combined approach for fertility preservation in women receiving pelvic radiation. *Fertil Steril*. 2007 Jan;87(1):189.e5-7.
 145. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. *British Journal of Surgery* 2012;99(7):918-28.
 146. McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. *Cochrane Database Syst Rev* 2012;12:CD008368.
 147. Memon S, Lynch AC, Akhurst T, Ngan SY, Warrier ST, Michael M, et al. Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer. *Ann Surg Oncol* 2014;21(11):3598-607.
 148. Merkel S, Mansmann U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. *Int J Colorectal Dis* 2001;16:298-304.
 149. Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, et al. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal cancer. *Ann Surg Oncol* 1994;1(2):111-6.
 150. Minsky BD, Coia L, Haller D, Hoffman J, John M, Landry J, et al. Treatment systems guidelines for primary rectal cancer from the 1996 patterns of care study. *Int J Radiat Oncol Biol Phys* 1998;41(1):21-7.
 151. Minsky BD. Preoperative combined modality treatment for rectal cancer. *Oncology (Williston Park)*. 199;8:53-8.
 152. Mohiuddin M, Paulus R, Mitchell E, Hanna N, Yuen A, Nichols R et al. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. *Int J Radiat Oncol Biol Phys* 2013;86(3):523-8.
 153. Mohiuddin M, Regine WF, John WJ, Hagihara PF, Mc Grath PC, Kenady DE, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. *Int J Radiat Oncol Biol Phys* 2000;46(4):883-8.
 154. Morice P, Castaigne D, Haie-Meder C, Pautier P, El Hassan J, Duvillard P, et al. Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes. *Fertil Steril* 1998;70(5):956-60.
 155. Morice P, Thiam-Ba R, Castaigne D, Haie-Meder C, Gerbaulet A, Pautier P, et al. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. *Hum Reprod* 1998;13(3):660-3.
 156. Moriya Y., Sugihara K., Akasu T, Fujita S. Importance of Extended Lymphadenectomy with Lateral Node Dissection for Advanced Lower Rectal Cancer *World Journal of Surgery* 1997;21(7):728-32.

157. Myerson R., Tan B, Hunt S., Olsen J., Birnbaum E, Fleshman J, Gao F, et al. Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. *Int J Radiat Oncol Biol Phys.* 2014;88(4):829–36.
158. Myerson RJ, Singh A, Birnbaum EH, Fry RD, Fleshman JW, Kodner JJ, et al. Pretreatment clinical findings predict outcome for patients receiving preoperative radiation for rectal cancer. *Int J Radiat Oncol Biol Phys* 2001;50(3):665–74.
159. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls (Accessed on May 06, 2021).
160. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. *J Clin Oncol* 2012;30(31):3827–33.
161. Nissan A, Stojadinovic A, Shia J, Hoos A, Guillem JG, Kimstra D, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. *J Clin Oncol* 2006;24(25):4078–84.
162. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. *JAMA* 1990;264(11):1444–50.
163. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. *N Engl J Med* 1994;331(8):502–7.
164. Ogura A, Konishi T, Cunningham Ch, Garcia Aguilar J, Iversen H, Toda S, et al. Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. *J Clin Oncol* 2019;37(1):33–43.
165. Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. *Ann Surg Oncol* 2001;8(10):801–6.
166. Onaitis MW, Noone RB, Hartwig M, Hurwitz H, Morse M, Jowell P, et al. Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. *Ann Surg* 2001;233(6):778–85.
167. Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. *Ann. Surg. Oncol.* 2001;8(10):801–6.
168. Park JJ, You YN, Agarwal A, Skibber JM, Rodriguez Bigas MA; Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. *J Clin Oncol* 2012;30(15):1770–6.
169. Pastor C, Subtil J, Sola J, Baixela J, Beorlegui C, Arbea L, et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? *Dis Colon Rectum* 2011;54(9):1141–6.
170. Patel UB, Blomqvist LK, Taylor F, George C, Guthrie A, Bees N, et al. MRI After Treatment of Locally Advanced Rectal Cancer: How to Report Tumor Response. The MERCURY Experience. *AJR* 2012;199(4):486–5.
171. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. *J Clin Oncol* 2011;29(28):3753–60.
172. Peeters KC, Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, Putter H, Wiggers T, et al. Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. *Ann Surg* 2007;246(5):693–701.
173. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburst JM, Klein Kranenbarg E, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. *J Clin Oncol* 2005;23(25):6199–206.
174. Perez RO, Habr-Gama A, Gama-Rodrigues J, Proscurshim I, Sao Juliao, GP, Lynn P, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). *Cancer* 2012;118(14):3501–11.
175. Perez RO, Habr-Gama A, São Julião GP, Proscurshim I, Fernandez L, de Azevedo RU, et al. Transanal Endoscopic Microsurgery (TEM) Following Neoadjuvant Chemoradiation for Rectal Cancer: Outcomes of Salvage Resection for Local Recurrence. *Ann Surg Oncol* 2016;23(4):1143–8.
176. Petersen SH, Harling H, Kirkeby LT, Wille Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. *Cochrane Database Syst Rev* 2012;3:CD004078.
177. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. *Br J Surg* 2012;99(4):577–83.
178. Pettersson D., Lörinc E., Holm T., Iversen H., Cedermark B., Glimelius B., Martling A. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. *Br J Surg* 2015;102(8):972–8.
179. Polanco PM, Mokdad AA, Zhu H, Choti MA, Huerta S. Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection. *JAMA Oncol* 2018;4(7):938–43.
180. Porter GA, Soskolne CL, Yakimets WW, Newman SC. Surgeon-related factors and outcome in rectal cancer. *Ann Surg* 1998;227(2):157–67.
181. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. *Dis Colon Rectum* 2004;47(11):1798–807.
182. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. *Lancet* 1986;328(8514):996–9.
183. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. *Lancet* 2009;373(9666):821–8.
184. Radu C, Berglund A, Pahlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. *Radiother Oncol* 2008;87(3):343–9.
185. Rau B, Hunerbein M, Barth C, Wust P, Haensch W, Riess H, et al. Accuracy of endorectal ultrasound after preoperative radiochemotherapy in locally advanced rectal cancer. *Surg Endosc* 1999;13(10):980–4.
186. Rengan R, Paty P, Wong WD, Guillem J, Weiser M, Temple L, et al. Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? *J Clin Oncol* 2005;23(22):4905–12.
187. Richardson B, Preskitt J, Lichliter W, Peschka S, Carmack S, de Prisco G, Fleshman J: The effect of multidisciplinary teams for rectal cancer on delivery of care and patient outcome: Has the use of multidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome? *Am J Surg* 2016;211(1):46–52.
188. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally

- advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2015;16(8):979-89.
189. Rodel C, Martus P, Papadopoulos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer. *J Clin Oncol* 2005;23(34):8688-96.
190. Rosenberg R, Nekarda H, Zimmermann F, Becker K, Lordick F, Hoffer H, et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. *J Surg Oncol* 2008;97(1):8-13.
191. Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. *Lancet* 2017;390(10093):469-79.
192. Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. *Lancet Gastroenterol Hepatol*. 2020;5(5):465-74.
193. Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. *Ann Surg* 2002;236(1):75-81.
194. Ruppert R, Kube R, Strassburg J, Lewin A, Baral J, Maurer CA, et al. Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial. *J Am Coll Surg* 2020;231(4):413-25.
195. Ryan ÉJ, O'Sullivan DP, Kelly ME, Syed AZ, Neary PC, O'Connell PR, et al. Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer. *Br J Surg* 2019;106(10):298-310.
196. Saglam S, Bugra D, Saglam EK, Asoglu O, Balik E, Yamaner S, et al. Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study. *J Gastrointest Oncol* 2014;5(1):9-17.
197. Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupatelli M, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). *Radiation Oncol* 2014;113(2):223-9.
198. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004;351(17):1731-40.
199. Schaffzin DM, Wong WD. Endorectal ultrasound in the preoperative evaluation of rectal cancer. *Clin Colorectal Cancer*. 2004;4(2):124-32.
200. Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, Daisne J-F, et al. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. *J Clin Oncol* 2021;39(1):17-29.
201. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol* 2014;32(6):513-8.
202. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. *Lancet* 2009;373(9666):811-20.
203. Shin SJ, Yoon HI, Kim NK, Lee KY, Min BS, Ahn JB, et al. Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. *Radiat Oncol*. 2011;6:99.
204. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7-30.
205. Simunovic M, Sexton R, Rempel E, Moran BJ, Heald RJ. Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy. *Br J Surg* 2003;90(8):999-1003.
206. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. *J Clin Oncol* 2006;24(22):3542-7.
207. Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, et al. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. *BMC Cancer* 2015;15:767.
208. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, et al. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. *JAMA Oncol* 2019;5:e185896.
209. Snelgrove RC, Subendran J, Jhaveri K, Thipphavong S, Cummings B, Brierley J, Kirsch R, Kennedy ED. Effect of multidisciplinary cancer conference on treatment plan for patients with primary rectal cancer. *Dis Colon Rectum* 2015;58(7):653-8.
210. Socha J, Kairevice L, Kepka L, Michalski W, Spalek M, Paciorek K, Bujko K. Should Short-Course Neoadjuvant Radiation Therapy Be Applied for Low-Lying Rectal Cancer? A Systematic Review and Meta-Analysis of the Randomized Trials. *Int J Radiat Oncol Biol Phys* 2020;108(5):1257-64.
211. Sprenger T, Rothe H, Conradi LC, Beissbarth T, Kauffels A, Kitz J, et al. Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup. *Dis Colon Rectum* 2016;59(5):377-85.
212. Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. *J Clin Oncol* 2010;28(27):4233-9.
213. Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuytens JJ, van Meerten E, et al. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study. *JAMA Surg* 2019;154(1):47-54.
214. Stipa F, Chessin DB, Shia J, Paty PB, Weiser M, Temple LK, et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. *Ann Surg Oncol* 2006;13(8):1047-53.
215. Stipa F, Zerneck A, Moore HG, Minsky BD, Wong WD, Weiser M, et al. Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection? *Ann Surg Oncol* 2004;11(2):187-91.
216. Stipa F, Chessin DB, Shia J, Paty PB, Weiser M, Temple LK, et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. *Ann Surg Oncol* 2006;13(8):1047-53.
217. Swedish Rectal Cancer Trial. Cedermark B, Dahlberg M, Climelius B, Pahlman L, Rutqvist LE, Wilking N. Improved survival with preoperative radiotherapy in resectable rectal cancer. *N Engl J Med* 1997;336(14):980-7.
218. Taylor FG, Quirke P, Heald RJ, Brendan M, Lennart B, Ian S, et

- al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. *Ann Surg* 2011;253(4):711-9.
219. Taflampas P, Christodoulakis M, Gourtsoyianni S, Leventi K, Melissas J, Tsiptsis DD. The effect of preoperative chemoradiotherapy on lymph node harvest after total mesorectal excision for rectal cancer. *Dis Colon Rectum* 2009;52(8):1470-4.
220. Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson 3rd AB, Cummings B, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114. *J Clin Oncol* 2002;20(7):1744-50.
221. Thomas J, George Jr TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. *Curr Colorectal Cancer Rep* 2015;11(5):275-80.
222. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. *Radiother Oncol* 1988;13(4):245-52.
223. Tinga DJ, Dolsma WV, Tamminga RY, van der Zee AG. Preservation of ovarian function in 2 young women with Hodgkin disease by laparoscopic transposition of the ovaries prior to abdominal irradiation. *Ned Tijdschr Geneesk* 1999;143(6):308-12.
224. Treisman MJ, Miller D, McComb PF. Laparoscopic lateral ovarian transposition. *Fertil Steril* 1996;65(6):1229-31.
225. Trotsyuk L, Sparschuh H, Müller AJ, Neumann K, Kruschewski M, Horst D, Elezkurtaj S. Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy. *BMC Cancer* 2019;19(1):1033.
226. Tulandi T, Al-Took S. Laparoscopic ovarian suspension before irradiation. *Fertil Steril* 1998;70(2):381-3.
227. Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. *Ann Surg Oncol* 2008;15(10):2661-7.
228. Turner MC, Keenan JE, Rushing CN, Gulack BC, Nussbaum DP, Benrashid E, et al. Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. *J Gastrointest Surg* 2019;23(8):1614-22.
229. Tyc-Szczepaniak D, Wyrwicz L, Kepka L, Michalski W, Olszyna-Serementa M, Palucki J, et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. *Ann Oncol* 2013;24(11):2829-34.
230. Ueno H, Mochizuki H, Hashiguchi Y, Ishiguro M, Miyoshi M, Kajiwara Y, et al. Potential Prognostic Benefit of Lateral Pelvic Node Dissection for Rectal Cancer Located Below the Peritoneal Reflection. *Ann Surg* 2007;245(1):80-7.
231. Ueno M, Oya M, Azekura K, Yamaguchi T, Muto T. Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. *Br J Surg* 2005;92(6):756-63.
232. Valentini V, Glimelius B, Minsky BD, van Cutsem E, Bartelink H, Beets-Tan RG, et al. The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus. *Radiother Oncol* 2005;76(3):241-50.
233. Valentini V, van Stiphout RGPM, Lammering G, Gambacorta MA, Barba MC, Bebenek M, et al. Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. *J Clin Oncol* 2011;29(23):3163-72.
234. van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S, et al. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. *Radiology* 2013;269(1):101-12.
235. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenberg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. *Lancet* 2018;391(10139):2537-45.
236. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Meershoek-Klein Kranenberg E, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. *Radiother Oncol* 2020;147:75-83.
237. Van de Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal Multidisciplinary management European consensus conference colon & rectum. *Eur J Cancer* 2014;50(1):1.e1-1.e34.
238. van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. *Ann Oncol* 2013;24(7):1762-9.
239. Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. *Am J Gastroenterol* 2004;38(1):35-40.
240. Vaughan-Shaw PG, Wheeler JM, Borley NR. The impact of a dedicated multidisciplinary team on the management of early rectal cancer. *Colorectal Dis* 2015;17(8):704-9.
241. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. *Int J Radiat Oncol Biol Phys* 2005;62(3):752-60.
242. Verhoef C, van der Pool AE, Nuytens JJ, Planting AS, Eggermont AM, de Witt JH. The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. *Dis Colon Rectum* 2009;52(1):23-30.
243. Verseveld M, de Graaf EJ, Verhoef C, van Meerten E, Punt CJ, de Hingh IH, et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). *Br J Surg* 2015;102(7):853-60.
244. Virginillo JM, Dieguez A, Leiro FO. Estadificación de pacientes con cáncer de recto por resonancia magnética de pelvis de alta resolución: relación entre hallazgos positivos de invasión vascular extramural y la presencia de metástasis hepáticas sincrónicas. Congreso Argentino de Cirugía 2011.
245. Wasserberg N, Kundel Y, Purim O, Keidar A, Kashtan H, Sadot E, Fenig E. Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy. *Radiation Oncology* 2014;9:233.
246. Weiser MR, Quah HM, Shia J, Guillem JG, Paty P, Temple L, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. *Ann Surg* 2009;249(2):236-42.
247. Wexner SD, Berho ME. The rationale for and reality of the New National Accreditation Program for Rectal Cancer. *Dis Colon Rectum* 2017;60(6):595-602.
248. Wijesuriya RE, Deen KI, Hewavisenthi J, Balawardana J, Perera M. Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly. *Surg Today* 2005;35(6):442-5.
249. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? *Dis Colon Rectum* 1999;42(2):167-73.
250. Willett CG. Intraoperative radiation therapy. *Int J Clin Oncol* 2001;6(5):209-14.
251. Wiltink LM, Chen TY, Nout RA, Meershoek-Klein Kranenberg E, Fiocco M, Laurberg S, et al. Health-related quality of life 14 years

- after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. *Eur J Cancer* 2014;50(14):2390-8.
252. Wu AW, Cai Y, Li YH, Wang L, Li ZW, Sun YS, Ji JF. Pattern and management of recurrence of mid-low rectal cancer after neoadjuvant intensity-modulated radiotherapy: Single-center results of 687 Cases. *Clin Colorectal Cancer* 2018;17: e307-e313.
253. Xiao L., Yu X., Deng W., Feng H., Chang H, Xiao W, et al. Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy. *Sci Rep* 2016;6:34923.
254. Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). *Ann Surg* 2010;252(6):998-1004.
255. You YN, Hardiman KM, Bafford A, Poylin V, Francone TD, Davis K, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer. *Dis Colon Rectum* 2020;63(9):1191-222.
256. Yothers G, George TJ, Petrelli NJ, O'Connell MJ, Beart RW, Allegra CJ, et al. Neoadjuvant rectal cancer (RC) score predicts survival: potential surrogate endpoint for early phase trials. *J Clin Oncol* 2014;32(5s):abstr 3533.
257. Zhang C, Tong J, Sun X, Liu J, Wang W, Huang G. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. *Int J Cancer* 2012;131(11):2604-11.
258. Zhao L, Liu R, Zhang Z, Li T, Li F, Liu H, et al. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. *Colorectal Dis* 2016;18(8):763-72.
259. Zhao RS, Wang H, Zhou ZY, Zhou Q, Mulholland MW. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis. *Dis Colon Rectum* 2014;57(3):388-95.
260. Zmora O, Dasilva GM, Gurland B, Pfeffer R, Koller M, Nogueras JJ, et al. Does rectal wall tumor eradication with preoperative chemoradiation permit a change in the operative strategy? *Dis Colon Rectum* 2004;47(10):1607-12.